Skip to main content
. Author manuscript; available in PMC: 2017 Jan 20.
Published in final edited form as: Nature. 2016 Jul 20;535(7612):382–387. doi: 10.1038/nature18325

Extended Data Fig. 1. Fork degradation in BRCA-deficient B lymphocytes is mediated by MRE11 exonuclease activity.

Extended Data Fig. 1

(a, b) Ratio of IdU vs. CldU upon HU treatment in (a) WT, Brca1−/− and (b) WT, Brca2−/− B lymphocytes with or without mirin pre-treatment. Numbers in red indicate the mean and standard deviation for each sample (ns, not significant, ** P ≤ 0.05, *** P ≤ 0.001, ****P ≤ 0.0001, Mann-Whitney test). 125 replication forks were analyzed for each genotype. (c) Ratio of IdU vs. CldU upon HU treatment in Brca2−/− B lymphocytes with or without mirin, PFM39 (MRE11 exonuclease inhibitor), PC5 (DNA2 inhibitor) or WRNi pre-treatment. Numbers in red indicate the mean and standard deviation for each sample (ns, not significant, ** P ≤ 0.05, ****P ≤ 0.0001, Mann-Whitney test). 125 replication forks were analyzed for each genotype.